 Acrivon Therapeutics Inc. on Thursday set an estimated price range of 16 to 18 a share in its upcoming initial public offering IPO on the Nasdaq under the symbol ACRV. With 5.9 million shares in the IPO, Acrivon Therapeutics will raise 100 million based on the midpoint of its estimated price range. 